Related Experiment Videos
Calcium channel blockers and hypertension: evolving perspective--1996
1Department of Medicine, University of Miami School of Medicine, Florida, USA.
Cardiovascular Drugs and Therapy
|January 1, 1997
Summary
Calcium channel blockers (CCBs) are versatile antihypertensive agents. Newer formulations with slow-release delivery may prevent adverse cardiovascular events by avoiding blood pressure fluctuations and sympathetic activation.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Calcium channel blockers (CCBs) are widely used for hypertension management.
- CCBs offer advantages over previous vasodilators, being metabolically neutral and beneficial for heart and kidney health.
- Recent analyses have raised concerns about CCBs potentially promoting adverse cardiovascular events.
Purpose of the Study:
- To review the impact of drug delivery rate on the cardiovascular effects of dihydropyridine CCBs.
- To address concerns regarding CCB safety and cardiovascular events.
Main Methods:
- Review of recent meta-analyses and published reports on CCB use.
- Analysis of hemodynamic and neurohumoral responses to dihydropyridine CCBs based on drug formulation and delivery rate.
Main Results:
- The rate of drug delivery significantly influences hemodynamic and neurohumoral responses to dihydropyridine CCBs.
- Short-acting CCB formulations can cause blood pressure fluctuations and intermittent sympathetic activation.
- Slow-release CCB formulations provide gradual, sustained antihypertensive effects, potentially mitigating adverse events.
Conclusions:
- The formulation and delivery rate of CCBs are critical factors in their cardiovascular safety.
- Newer CCB formulations designed for sustained release are less likely to provoke adverse cardiovascular events.
- Optimizing CCB delivery may enhance their therapeutic profile in hypertension management.